In subjects with metastatic malignant melanoma of the CNS, immunotherapy based on checkpoint inhibition (anti-programmed death-1 or anti-CTLA-4) has shown marked activity in recent years. This evidence concerns the gene CTLA4 and metastatic melanoma.